4569.T Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 08:15):

Stats
Tagesvolumen	84 900.00
Durchschnittsvolumen	69 440.00
Marktkapitalisierung	105.02B
EPS	¥0 ( 2024-02-05 )
Nächstes Ertragsdatum	( ¥0 ) 2024-05-08
Last Dividend	¥32.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	24.63
ATR14	¥1.224 (0.07%)

Volumen Korrelation

Lang: 0.12 (neutral)

Kurz: 0.91 (very strong)

Signal:(59.072) Expect same movement, but be aware

KYORIN Holdings, Inc. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

KYORIN Holdings, Inc. Korrelation - Währung/Rohstoff

0.74
( moderate )

0.86
( strong )

-0.19
( neutral )

0.86
( strong )

-0.19
( neutral )

-0.87
( strong negative )

KYORIN Holdings, Inc. Finanzdaten

Annual	2022
Umsatz:	¥113.27B
Bruttogewinn:	¥50.17B (44.29 %)
EPS:	¥82.42

FY	2022
Umsatz:	¥113.27B
Bruttogewinn:	¥50.17B (44.29 %)
EPS:	¥82.42

FY	2022
Umsatz:	¥105.53B
Bruttogewinn:	¥49.44B (46.85 %)
EPS:	¥68.62

FY	2021
Umsatz:	¥102.90B
Bruttogewinn:	¥51.63B (50.17 %)
EPS:	¥106.99

Financial Reports:

No articles found.

KYORIN Holdings, Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥20.00 (N/A)	¥0 (N/A)	¥32.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

KYORIN Holdings, Inc. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.34 - Stable (13.14%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥10.00	2006-09-26
Last Dividend	¥32.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	35	--
Total Paid Out	¥862.50	--
Avg. Dividend % Per Year	0.00%	--
Score	3.6	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.34
Div. Directional Score	7.48	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

3.60

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8369.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
7762.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6937.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6294.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
5018.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
4220.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3434.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2540.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9468.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
8097.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0356	1.500	9.29	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0238	1.200	9.21	10.00	[0 - 0.3]
returnOnEquityTTM	0.0339	1.500	-0.735	-1.102	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.53	0.800	2.34	1.871	[1 - 3]
quickRatioTTM	1.327	0.800	6.90	5.52	[0.8 - 2.5]
cashRatioTTM	0.402	1.500	8.88	10.00	[0.2 - 2]
debtRatioTTM	0.116	-1.500	8.06	-10.00	[0 - 0.6]
interestCoverageTTM	75.14	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.164	-1.500	9.34	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.429	1.000	6.18	6.18	[0.2 - 0.8]
operatingProfitMarginTTM	0.0408	1.000	-1.185	-1.185	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.405	1.000	8.86	8.86	[0.2 - 2]
assetTurnoverTTM	0.670	0.800	8.87	7.10	[0.5 - 2]
Total Score				10.62

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.65	1.000	7.61	0	[1 - 100]
returnOnEquityTTM	0.0339	2.50	-0.472	-1.102	[0.1 - 1.5]
freeCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.84	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.226	1.500	5.16	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0702	1.000	-0.745	0	[0.1 - 0.5]
Total Score				4.34

KYORIN Holdings, Inc.

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.